Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Design of the rivaroxaban for heparin-induced thrombocytopenia study.
[heparin-induced thrombocytopenia]
Rivaroxaban
is
an
ideal
potential
candidate
for
treatment
of
heparin-induced
thrombocytopenia
(
HIT
)
because
it
is
administered
orally
by
fixed
dosing
,
requires
no
laboratory
monitoring
and
is
effective
in
the
treatment
of
venous
and
arterial
thromboembolism
in
other
settings
.
The
Rivaroxaban
for
HIT
study
is
a
prospective
,
multicentre
,
single
-arm
,
cohort
study
evaluating
the
incidence
of
new
symptomatic
venous
and
arterial
thromboembolism
in
patients
with
suspected
or
confirmed
HIT
who
are
treated
with
rivaroxaban
.
Methodological
challenges
faced
in
the
design
of
this
study
include
heterogeneity
of
the
patient
population
,
differences
in
the
baseline
risk
of
thrombosis
and
bleeding
dependent
on
whether
HIT
is
confirmed
or
just
suspected
,
and
heterogeneity
in
laboratory
confirmation
of
HIT
.
The
rationale
for
how
these
challenges
were
addressed
and
the
final
design
of
the
Rivaroxaban
for
HIT
study
is
reviewed
.
